Prostheses in the ossicular chain. II. Construction of prosthesis for the incus: postoperative study of the data.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to T Gundersen.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Of 92 men with gonococcal urethritis who were treated orally with amoxicillin, 25 (27.1%) had a simultaneous Chlamydia trachomatis infection. At the first visit 25 patients were treated with a single dose of 1 g of amoxicillin plus 1 g of probenecid (group 1); 24 men were treated with 1 g of amoxicillin twice a day for two days (group 2); and 43 men were treated with 0.75 mg of amoxicillin three times a day for seven days (group 3). At the follow-up visit, one patient in each group still had Neisseria gonorrhoeae-positive cultures. C. trachomatis was not isolated again after treatment from men in group 3, but was isolated from 81.8% in groups 1 and 2 combined (P less than 0.05). One (10%) of the ten men in group 3 who were C. trachomatis-positive before treatment developed postgonococcal urethritis, as compared with seven (63.6%) of 11 in groups 1 and 2 combined (P less than 0.05). Thus a multiple-dose amoxicillin regimen may prove to be a useful alternative to the present-day treatment of chlamydial infections of the urogenital tract.
In diabetic patients long-term treatment with timolol after myocardial infarction was related to a reduction in overall mortality, total cardiac death, sudden death, and nonfatal reinfarction, compared with patients in a placebo group. The analyses were based on 99 diabetic patients in the Norwegian timolol multicenter study. The dosage of timolol was 10 mg twice daily and the follow-up period was 12-33 mo (mean: 17 mo). When analyzing all randomized patients, there were 14 deaths in the placebo group and 6 deaths in the timolol group, a reduction of 62.8% (P less than 0.05). The number of nonfatal reinfarctions was 10 in the placebo group and 2 in the timolol group, a reduction of 82.7% (P less than 0.05). With regard to inclusion rate, side effects, withdrawals, and timolol-related reduction in mortality and reinfarction, the diabetic patients basically behaved like nondiabetic patients. The data were analyzed retrospectively and should be confirmed by a prospective study. The study also indicates that long-term treatment with timolol may induce slight carbohydrate intolerance.